How Does Amycretin Work? Mechanism of Action, Per the Research

Amycretin is an investigational medicine currently under study in clinical trials and is not an approved product. Published pharmacology describes it as a unimolecular agonist, meaning one peptide molecule engineered to activate two separate receptor systems: the glucagon-like peptide-1 (GLP-1) receptor and the amylin receptor family. A phase 1b/2a randomised controlled study of subcutaneous amycretin characterised it in exactly those terms, as a novel unimolecular GLP-1 and amylin receptor agonist (PMID 40550231), and a first-in-human phase 1 trial described the same compound as a first-in-class GLP-1 and amylin receptor agonist (PMID 40550229).

This page is for educational purposes only and is not medical advice; consult a licensed physician about any question concerning diagnosis, treatment or investigational medicines. For a broader overview of the compound, see the Amycretin learn page.

The Short Answer: Two Receptor Systems, One Molecule

The mechanistic claim made in the literature is straightforward in outline. Amylin and GLP-1 are both endogenous peptide hormones that signal satiation and help regulate glucose handling, and they do so through different receptors and partly different neural circuits. A 2026 mechanism-focused review of amycretin in obesity summarised the rationale for combining both activities within one peptide, covering mechanisms, clinical efficacy and future perspectives (PMID 41850421). Broader reviews of multifunctional incretin peptides have placed this design within a wider trend of single molecules carrying two or more receptor activities for type 2 diabetes, obesity and associated co-morbidities (PMID 40081498).

Target 1: The GLP-1 Receptor

The GLP-1 receptor is a class B G protein coupled receptor expressed in pancreatic islet beta cells, in regions of the brain involved in appetite and nausea, and in several peripheral tissues. Reviews of GLP-1 based medications for type 2 diabetes and obesity describe the canonical signalling route, in which receptor activation couples to Gs proteins, raises intracellular cyclic AMP and activates protein kinase A and related effectors (PMID 41054801).

Downstream physiology attributed to GLP-1 receptor activation

• Glucose-dependent insulin secretion. Reviews of GLP-1 based medications describe amplification of insulin release that depends on prevailing glucose concentrations (PMID 41054801).
• Glucagon regulation. The same review literature covers suppression of inappropriately elevated glucagon as part of the incretin effect (PMID 41054801).
• Slowed gastric emptying. Reviews of multifunctional incretin peptides describe delayed gastric emptying as a contributor to reduced post-meal glucose excursions and to earlier fullness (PMID 40081498).
• Central appetite signalling. Reviews of GLP-1 based medicines attribute reduced energy intake to receptor populations in hypothalamic and hindbrain circuits (PMID 41054801).

A 2026 review looking beyond weight loss at the multisystem effects of obesity medications discussed how GLP-1 receptor expression outside the pancreas and brain has been linked to effects in cardiovascular, renal and hepatic tissue (PMID 42208956). That breadth is one reason reviewers treat tissue-level mechanism as an active research question rather than a closed one.

Target 2: The Amylin Receptors

Amylin, also called islet amyloid polypeptide, is co-secreted with insulin from beta cells. Its receptors are not standalone proteins in the usual sense: they are formed when the calcitonin receptor associates with receptor activity-modifying proteins, generating the AMY receptor subtypes. A 2026 review of long-acting amylin-related peptides as therapies for obesity and type 2 diabetes set out this receptor architecture and the pharmacology of the peptide class (PMID 41747885).

Downstream physiology attributed to amylin receptor activation

• Meal-ending satiation. The amylin-related peptide review describes signalling in the area postrema and connected hindbrain nuclei as central to the satiation effect of this class (PMID 41747885).
• Gastric emptying and post-meal glucagon. The same review covers amylin's effects on gastric emptying and on nutrient-stimulated glucagon (PMID 41747885).
• A distinct circuit from GLP-1. Reviews of incretin co-agonists frame amylin pharmacology as complementary to incretin pharmacology rather than redundant with it (PMID 40949933).

Established Mechanism Versus Proposed Mechanism

It is worth separating what the published pharmacology treats as settled from what remains hypothesis under test.

What the Animal Work Described

The following paragraph describes preclinical research in rodents, not human findings. A 2025 study published in EBioMedicine examined the effect of amycretin, described there as a unimolecular GLP-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats (PMID 40706446). The study used rodent models to characterise how the dual receptor activity translated into measurable metabolic endpoints, and researchers reported on both body weight and markers of metabolic dysfunction in those animals (PMID 40706446). Rodent metabolic physiology differs from human physiology in receptor distribution, energy expenditure and feeding behaviour, so animal findings are treated in the literature as mechanistic groundwork rather than as predictions of clinical outcome.

What the Human Trials Assessed

Two early-phase human trials have been published. The first-in-human phase 1, double-blind, randomised, placebo-controlled trial evaluated safety, tolerability, pharmacokinetics and pharmacodynamics of amycretin (PMID 40550229). Pharmacodynamics in this context refers to the measurable biological responses that follow receptor engagement, which is how a mechanism proposed from cell and animal work is checked in people.

A separate phase 1b/2a randomised controlled study investigated subcutaneously administered amycretin (PMID 40550231). Studying more than one route of administration matters mechanistically because absorption and exposure profiles shape how sustained receptor activation is, which in turn shapes both the physiological response and tolerability. Questions about administration, suitability or candidacy are clinical matters for a prescribing physician and are outside the scope of an educational summary.

How This Design Sits Within the Wider Class

Amycretin belongs to a wave of multi-receptor peptides. A 2025 review of multifunctional incretin peptides catalogued molecules combining incretin activity with other receptor targets for type 2 diabetes, obesity and associated co-morbidities (PMID 40081498). A 2025 review of incretin co-agonists examined efficacy and safety evidence across cardiometabolic care (PMID 40949933), and a 2026 updated systematic review in Annals of Internal Medicine assessed GLP-1 receptor agonists and co-agonists for weight loss among adults without diabetes (PMID 42673585). A 2026 review in The Journal of Clinical Endocrinology and Metabolism surveyed what the future may hold for medical treatments of obesity, placing investigational dual-receptor peptides in that forward-looking context (PMID 42444567).

For comparison, approved medicines already act on part of this system. A 2025 systematic review compared semaglutide, liraglutide, orlistat and phentermine for weight loss in people with obesity (PMID 40206909). Those GLP-1 receptor agonists engage one of the two receptor families that amycretin targets, which is why class-level pharmacology is often used as the reference frame when amycretin's mechanism is discussed (PMID 41054801).

Tolerability and Adverse Events: What Studies Report

The first-in-human phase 1 trial was designed to evaluate safety and tolerability alongside pharmacokinetics and pharmacodynamics (PMID 40550229), and the phase 1b/2a randomised controlled study of subcutaneous amycretin similarly reported trial results within a randomised, controlled design (PMID 40550231). At the class level, reviews of GLP-1 based medications for type 2 diabetes and obesity have discussed the safety profile of these agents, with gastrointestinal effects as the most frequently described category (PMID 41054801). The 2026 updated systematic review of GLP-1 receptor agonists and co-agonists likewise assessed both efficacy and safety among adults without diabetes (PMID 42673585), and a 2025 review of incretin co-agonists evaluated efficacy and safety across cardiometabolic indications (PMID 40949933).

Mechanistically, the same receptors that mediate reduced food intake are expressed in brainstem regions associated with nausea, which is why reviews of amylin-related peptides and of incretin peptides discuss tolerability alongside efficacy rather than as a separate topic (PMID 41747885). Interpretation of any individual safety signal belongs with a licensed physician.

What Remains Unresolved

• Relative contribution of each receptor. The 2026 mechanism review of amycretin in obesity addressed mechanisms alongside clinical efficacy and future perspectives, indicating that the apportionment between GLP-1 and amylin signalling is still an open research question (PMID 41850421).
• Long-term and multisystem effects. A 2026 review examined multisystem effects of obesity medications beyond weight loss, a domain where evidence continues to accumulate (PMID 42208956).
• Translation from rodents to people. The rodent study characterised effects on body weight and metabolic dysfunction in mice and rats (PMID 40706446), and human confirmation of each mechanistic step requires dedicated clinical pharmacology work (PMID 40550229).

Regulatory Status, Stated Positively

Amycretin's status is that of an investigational medicine evaluated in registered clinical trials, with phase 1 and phase 1b/2a results published in the peer-reviewed literature (PMID 40550229, PMID 40550231). Approved medicines acting on the GLP-1 receptor, including semaglutide and liraglutide, have been compared with other weight-management agents in a 2025 systematic review (PMID 40206909). Every question about eligibility, prescription or medical use belongs with a prescribing clinician.

References

• Safety, tolerability, pharmacokinetics, and pharmacodynamics of the first-in-class GLP-1 and amylin receptor agonist, amycretin: a first-in-human, phase 1, double-blind, randomised, placebo-controlled trial (Lancet, 2025)
• Amycretin, a novel, unimolecular GLP-1 and amylin receptor agonist administered subcutaneously: results from a phase 1b/2a randomised controlled study (Lancet, 2025)
• Amycretin in obesity: Mechanisms, clinical efficacy, and future perspectives (Metabolism: Clinical and Experimental, 2026)
• The effect of amycretin, a unimolecular glucagon-like peptide-1 and amylin receptor agonist, on body weight and metabolic dysfunction in mice and rats (EBioMedicine, 2025)
• Novel GLP-1-based Medications for Type 2 Diabetes and Obesity (Endocrine Reviews, 2026)
• Long-acting amylin-related peptides as therapies for obesity and type 2 diabetes (Peptides, 2026)
• Multifunctional incretin peptides in therapies for type 2 diabetes, obesity and associated co-morbidities (Peptides, 2025)
• Efficacy and safety of incretin co-agonists: Transformative advances in cardiometabolic healthcare (World Journal of Cardiology, 2025)
• Efficacy and Safety of Glucagon-like Peptide-1 Receptor Agonists and Co-agonists for Weight Loss Among Adults Without Diabetes: An Updated Systematic Review (Annals of Internal Medicine, 2026)
• Beyond weight loss: multisystem benefits of obesity medications (The Lancet Diabetes & Endocrinology, 2026)
• Medical treatments for obesity: what does the future have in store? (The Journal of Clinical Endocrinology and Metabolism, 2026)
• Comparative Effectiveness of Semaglutide, Liraglutide, Orlistat, and Phentermine for Weight Loss in Obese Individuals: A Systematic Review (Cureus, 2025)